.jpg "Ultragenyx (NASDAQ: RARE)")
Today, a Director at Ultragenyx (NASDAQ: RARE), William Aliski, sold shares of RARE for $287.5K.
Following William Aliski’s last RARE Sell transaction on January 25, 2018, the stock climbed by 19.5%.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $12.79 million and GAAP net loss of $52.73 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $72.89 million. Currently, Ultragenyx has an average volume of 434.2K.
Based on 12 analyst ratings, the analyst consensus is Strong Buy with an average price target of $85.91, reflecting a -9.7% downside.
The insider sentiment on Ultragenyx has been negative according to 56 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
